

PATIENT INFORMATION

PATIENT NAME	CELLMAX SAMPLE ID	DATE SPECIMEN COLLECTED
John Doe	SCL_180001	01/13/2018
DOB	MEDICAL RECORD NUMBER	DATE SPECIMEN RECEIVED
03/01/1956	123456ABC	01/15/2018
GENDER	ORDERING PHYSICIAN	REPORT DATE
Male	Dr. Jackie Meahoff	01/20/2018

RESULT

Negative

An individual with a negative result is less likely to have adenomatous polyps or colorectal cancer. Periodic testing is recommended using an interval and method defined by the physician.

TEST DESCRIPTION

FirstSight is a blood test for assessing the likelihood of adenomatous polyps (pre-cancer) or colorectal cancer based on an algorithm developed from a clinical study.

LIMITATIONS AND PRECAUTIONS

FirstSight assesses the likelihood of having adenomatous polyps or colorectal cancer in average risk adults of either sex, age 45 and older. A negative result does not guarantee the absence of colorectal cancer (CRC) or adenomatous polyps (pre-cancer). The test may produce a positive result, in the absence of colorectal cancer or adenomatous polyps by structural examination such as colonoscopy. The performance of FirstSight has been established in a clinical study. Additional description of the CellMax Life test process, warnings, and descriptions can also be found at www.cellmaxlife.com.